Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies
Abstract The addition of targeted therapies (TT) to endocrine therapy (ET) has improved the outcomes of patients with HR-positive, HER2-negative metastatic breast cancer (mBC). However, it is unknown whether patients with invasive lobular carcinoma (ILC) or mixed invasive ductal and lobular carcinom...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-12-01
|
| Series: | npj Breast Cancer |
| Online Access: | https://doi.org/10.1038/s41523-022-00499-7 |
| _version_ | 1797422448619028480 |
|---|---|
| author | Jason A. Mouabbi Akshara Singareeka Raghavendra Roland L. Bassett Amy Hassan Debu Tripathy Rachel M. Layman |
| author_facet | Jason A. Mouabbi Akshara Singareeka Raghavendra Roland L. Bassett Amy Hassan Debu Tripathy Rachel M. Layman |
| author_sort | Jason A. Mouabbi |
| collection | DOAJ |
| description | Abstract The addition of targeted therapies (TT) to endocrine therapy (ET) has improved the outcomes of patients with HR-positive, HER2-negative metastatic breast cancer (mBC). However, it is unknown whether patients with invasive lobular carcinoma (ILC) or mixed invasive ductal and lobular carcinoma (mixed) histologies experience the same magnitude of benefit from this therapy as those with invasive ductal carcinoma (IDC). We aim to determine whether patients with IDC, ILC, and mixed HR+/HER2− mBC derive similar benefit from the addition of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is), mammalian target of rapamycin inhibitor (mTORi), and phosphoinositide 3-kinase inhibitor (PI3Ki) to ET in HR+/HER2− mBC. We conducted an observational, population-based investigation using data from the MD Anderson prospectively collected database. We conducted a histology-based analysis of progression-free survival (PFS) and overall survival (OS) durations in 3784 patients with HR+/HER2− mBC who were treated with TT plus ET between January 1, 2010, and December 31, 2021. Out of the 3784 patients, 2975 were included in the final analysis. Of these, 2249 received CDK4/6is (81% IDC, 15% ILC, and 4% mixed), 1027 received everolimus (82% IDC, 14% ILC, and 4% mixed) and 49 received alpelisib (81% IDC and 19% ILC). The addition of targeted therapy to ET did not result in statistically significant differences in PFS or OS duration among patients with IDC, ILC, and mixed HR+/HER2− mBC. We concluded that for patients with HR+/HER2− mBC, the addition of TT to ET leads to a similar magnitude of benefit, irrespective of histology. |
| first_indexed | 2024-03-09T07:32:27Z |
| format | Article |
| id | doaj.art-982f3e9cb56b48ee9ecd4add8542b9a0 |
| institution | Directory Open Access Journal |
| issn | 2374-4677 |
| language | English |
| last_indexed | 2024-03-09T07:32:27Z |
| publishDate | 2022-12-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Breast Cancer |
| spelling | doaj.art-982f3e9cb56b48ee9ecd4add8542b9a02023-12-03T05:53:45ZengNature Portfolionpj Breast Cancer2374-46772022-12-01811710.1038/s41523-022-00499-7Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapiesJason A. Mouabbi0Akshara Singareeka Raghavendra1Roland L. Bassett2Amy Hassan3Debu Tripathy4Rachel M. Layman5Department of Breast Medical Oncology, Unit 1354, The University of Texas MD Anderson Cancer CenterDepartment of Breast Medical Oncology, Unit 1354, The University of Texas MD Anderson Cancer CenterDepartment of Biostatistics, Unit 1411, The University of Texas MD Anderson Cancer CenterDepartment of General Oncology, Unit 462, The University of Texas MD Anderson Cancer CenterDepartment of Breast Medical Oncology, Unit 1354, The University of Texas MD Anderson Cancer CenterDepartment of Breast Medical Oncology, Unit 1354, The University of Texas MD Anderson Cancer CenterAbstract The addition of targeted therapies (TT) to endocrine therapy (ET) has improved the outcomes of patients with HR-positive, HER2-negative metastatic breast cancer (mBC). However, it is unknown whether patients with invasive lobular carcinoma (ILC) or mixed invasive ductal and lobular carcinoma (mixed) histologies experience the same magnitude of benefit from this therapy as those with invasive ductal carcinoma (IDC). We aim to determine whether patients with IDC, ILC, and mixed HR+/HER2− mBC derive similar benefit from the addition of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is), mammalian target of rapamycin inhibitor (mTORi), and phosphoinositide 3-kinase inhibitor (PI3Ki) to ET in HR+/HER2− mBC. We conducted an observational, population-based investigation using data from the MD Anderson prospectively collected database. We conducted a histology-based analysis of progression-free survival (PFS) and overall survival (OS) durations in 3784 patients with HR+/HER2− mBC who were treated with TT plus ET between January 1, 2010, and December 31, 2021. Out of the 3784 patients, 2975 were included in the final analysis. Of these, 2249 received CDK4/6is (81% IDC, 15% ILC, and 4% mixed), 1027 received everolimus (82% IDC, 14% ILC, and 4% mixed) and 49 received alpelisib (81% IDC and 19% ILC). The addition of targeted therapy to ET did not result in statistically significant differences in PFS or OS duration among patients with IDC, ILC, and mixed HR+/HER2− mBC. We concluded that for patients with HR+/HER2− mBC, the addition of TT to ET leads to a similar magnitude of benefit, irrespective of histology.https://doi.org/10.1038/s41523-022-00499-7 |
| spellingShingle | Jason A. Mouabbi Akshara Singareeka Raghavendra Roland L. Bassett Amy Hassan Debu Tripathy Rachel M. Layman Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies npj Breast Cancer |
| title | Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies |
| title_full | Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies |
| title_fullStr | Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies |
| title_full_unstemmed | Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies |
| title_short | Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies |
| title_sort | histology based survival outcomes in hormone receptor positive metastatic breast cancer treated with targeted therapies |
| url | https://doi.org/10.1038/s41523-022-00499-7 |
| work_keys_str_mv | AT jasonamouabbi histologybasedsurvivaloutcomesinhormonereceptorpositivemetastaticbreastcancertreatedwithtargetedtherapies AT aksharasingareekaraghavendra histologybasedsurvivaloutcomesinhormonereceptorpositivemetastaticbreastcancertreatedwithtargetedtherapies AT rolandlbassett histologybasedsurvivaloutcomesinhormonereceptorpositivemetastaticbreastcancertreatedwithtargetedtherapies AT amyhassan histologybasedsurvivaloutcomesinhormonereceptorpositivemetastaticbreastcancertreatedwithtargetedtherapies AT debutripathy histologybasedsurvivaloutcomesinhormonereceptorpositivemetastaticbreastcancertreatedwithtargetedtherapies AT rachelmlayman histologybasedsurvivaloutcomesinhormonereceptorpositivemetastaticbreastcancertreatedwithtargetedtherapies |